stockrowPhathom Pharmaceuticals, Inc.
PHAT Healthcare Biotechnology
Phathom Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $175.1 million, up 216.9% from fiscal 2024.
- Revenue
- +71.1%
- EPS
- +60.1%
- Free cash flow
- +112.2%
- Total debt
- −20.1%
Quarter to September 2026, against a year earlier
Follow PHAT
Alert me
Phathom Pharmaceuticals, Inc. (PHAT) EV/Sales
As of 6 November 2026, Phathom Pharmaceuticals, Inc. (PHAT) trades at a EV/Sales of 1.6×. Over the past ten years it has ranged from 0.0× (December 2024) to 9.6× (June 2025); the current reading is higher than 74% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 7.4× | (4.11%) |
| FY2024 | 7.7× | — |
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 2.2× | (40.88%) |
| Jun 2026 | 3.8× | (14.85%) |
| Mar 2026 | 4.4× | (40.49%) |
| Dec 2025 | 7.4× | 15.42% |
| 7 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| PRTCY PureTech Health PLC Sponsored ADR compare | −9.1× |
| ARVN Arvinas, Inc. compare | −0.5× |
| RLMD Relmada Therapeutics, Inc. compare | n/m |
| CRMD CorMedix Inc compare | 0.7× |
| ASMB Assembly Biosciences, Inc. compare | 0.8× |
| PHAT Phathom Pharmaceuticals, Inc. | 1.6× |
| PRTA Prothena Corporation plc compare | 2.6× |
| GYRE Gyre Therapeutics, Inc. compare | 3.5× |
| OCS Oculis Holding AG compare | 176× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)